You are here: Industry Insights > SpringWorks

News List

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations drugs
August 06, 2021
SpringWorks Therapeutics, Inc. today announced that the Company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study sponsored by Memorial Sloan Kettering Cancer Center (MSK)
SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference firstwordpharma
June 16, 2021
SpringWorks Therapeutics, Inc.today announced that an update on the previously reported interim data from the first 20 adult patients enrolled in the ongoing Phase 2b ReNeu trial evaluating mirdametinib.
SpringWorks, Janssen to Evaluate Nirogacestat with Teclistamab for Multiple Myeloma americanpharmaceuticalreview
September 21, 2020
SpringWorks Therapeutics has entered into a clinical collaboration and supply agreement with Janssen Biotech to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody ...
SpringWorks receives orphan status for nirogacestat in Europe pharmaceutical-technology
September 27, 2019
US-based SpringWorks Therapeutics has received orphan drug designation from the European Commission (EC) for its small molecule candidate nirogacestat to treat soft tissue sarcoma.
SpringWorks receives breakthrough status for desmoid tumour drug pharmaceutical-technology
September 03, 2019
SpringWorks Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for nirogacestat...
SpringWorks and GSK sign clinical trial collaboration agreement pharmaceutical-technology
July 01, 2019
SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKline’s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma.